Resources

VIDEOS

60 Minutes: Nine veterans with PTSD went to Mexico for a psychedelic retreat. This is how they feel nearly a year later.

In a recent episode 60 Minutes joines U.S. veterans with PTSD as they attend a week-long psychedelic retreat in Mexico. Nearly a year later, most of the vets say the experience with psylocibin was life-changing.

Rick Perry MAPS 2023

Experts discuss LSD’s effects, SSRIs, dosing methods, and trip duration insights in this Q&A session.

How to Change Your Mind

Renowned author Michael Pollan embarks on a journey to investigate the historical significance and diverse applications of psychedelics, encompassing substances like LSD, psilocybin, MDMA, and mescaline, in this captivating Netflix series.

A New Understanding

A New Understanding explores the treatment of end-of-life anxiety in terminally ill cancer patients using psilocybin, a psychoactive compound found in some mushrooms, to facilitate deeply spiritual experiences. The documentary explores the confluence of science and spirituality in the first psychedelic research studies since the 1970s with terminally ill patients

Governor Rick Perry speaks on a study on Veterans facing severe PTSD, traumatic brain injuries, and addiction that shows great promise.

Recently, on the Joe Rogan Experience Podcast, Governor Perry and Bryan Hubbard discussed the transformative potential of psychedelic therapies for Veterans with PTSD. Governor Perry highlighted a groundbreaking study showing remarkable recovery among Veterans facing severe PTSD, traumatic brain injuries, and addiction challenges, emphasizing the urgent need to expand access to these treatments.

New hope in treating PTSD with psychedelic drugs

Explore CBS’s story on an FDA-approved MDMA trial for PTSD that showcases promising results.

David Nichols, PhD: Psychedelic Neuroscience: LSD Gives Up a Secret

Dr. David Nichols explains the molecular mechanisms behind LSD’s effects on the brain, focusing on its interaction with serotonin receptors and the role of arrestin in its psychoactive properties.

How Magic Mushrooms are Used for Healing | The New Yorker

Eddie Marritz, a cinematographer and photographer in remission from small-cell carcinoma, shares his transformative experience as a participant in NYU’s Psilocybin Cancer Anxiety research study.

Psilocybin, Addiction, and End of Life - Stephen Ross

Dr. Stephen Ross presents findings from the NYU Psychedelic Research Group’s study on psilocybin-assisted psychotherapy for advanced cancer patients, highlighting reductions in death anxiety, existential distress, and depression, along with increased spiritual well-being and improved family dynamics.

Stephen Ross & Gabby Agin Liebes: Psilocybin for Cancer Related Anxiety & Depression - NYU Trial

Dr. Steven Ross and Dr. Gabby Agin Liebes discuss a ten-year clinical trial exploring the use of psilocybin-assisted psychotherapy to treat cancer-related psychological distress.

Healthy Minds: Psychedelic-Assisted Psychotherapy and Post-Traumatic Stress

Psychedelic drugs show promise in treating post-traumatic stress when administered under trained therapist guidance. Dr. Rachel Yehuda, a trauma research expert, explores these breakthroughs in patient perspectives.

David Nichols & Franz Vollenweider Q&A: Psychedelic Neuroscience

Experts discuss LSD’s effects, SSRIs, dosing methods, and trip duration insights in this Q&A session.

Rosalind Watts: Psilocybin & Patient Reports of Increased Connection to Self, Others, and World

Dr. Rosalind Watts discusses the Psilocybin for Depression Study, highlighting how participants shifted from feeling disconnected to experiencing increased connection to themselves, others, and the world.

The Therapeutic Potential of Mood-Altering Substances: Roland Griffiths at TEDx

Roland Griffiths, Ph.D., explores the behavioral and subjective effects of mood-altering substances and their therapeutic potential in this TEDx talk.

Neurobiology of Psychedelics: Implication for Mood Disorders - Franz Vollenweider

Dr. Franz X. Vollenweider discusses recent advances in the neurobiology of psychedelics like psilocybin, focusing on its ability to enhance mood and regulate emotions.

Roland Griffiths: Johns Hopkins Psilocybin Project - Implications for Spirituality & Therapeutics

Dr. Roland Griffith’s research at Johns Hopkins explores psilocybin’s ability to induce mystical experiences, showing lasting positive effects on well-being and life satisfaction, with potential therapeutic benefits for psychological distress.

TESTIMONIALS

Chad Kuske, Former Navy SEAL and Psilocybin Therapy Advocate

In the video presentation, Kuske, a former Navy special operations veteran with nearly two decades of service, delves into his personal journey with PTSD and elaborates on how he has harnessed the potential of psilocybin as an impactful therapeutic solution.

Cathy's Journey: Psilocybin for Smoking Cessation

In a Johns Hopkins smoking cessation trial, Cathy, a lifelong smoker, successfully quit and has stayed smoke-free. This study highlights the potential of innovative methods in overcoming nicotine addiction.

Overcoming Cancer Anxiety: Richard's Journey with Psilocybin

Richard joined a psilocybin study at Johns Hopkins to address anxiety tied to his cancer diagnosis. The study demonstrated promising results in reducing anxiety and enhancing emotional well-being for patients facing life-threatening conditions.

Overcoming Cancer Anxiety: Tony

Tony, a cancer patient battling anxiety, found relief through a transformative psilocybin study at Johns Hopkins.

Annie Levy - Psilocybin Study Participant

Cancer patient Annie Levy recounts her transformative psilocybin experience at Harbor-UCLA Medical Center. She shares how the psychedelic journey impacted her emotional well-being and provided significant results in her battle with cancer.

Kershman: Benefits from the Johns Hopkins Psilocybin Study

Cancer patient Lauri Kershman, M.D., shares her powerful experience as a participant in the John Hopkins Psilocybin Study, supported by the Heffter Research Institute. She discusses how psilocybin impacted her emotional and psychological journey while battling cancer.

"The Substance" - Interview with Johns Hopkins Psilocybin Cancer Project Participant 1

This interview is part of the documentary The Substance. A volunteer participant in the Johns Hopkins Psilocybin Cancer Project, supported by the Heffter Research Institute, recounts their experience with psilocybin and the significant effects it had on their cancer journey.

UNM Alcohol Dependence Study: Sarah

Sarah discusses the impact of the study on her journey with alcohol dependence and the insights gained from the groundbreaking research on psychedelic therapy.

Kershman: Benefits from the Johns Hopkins Psilocybin Study

Cancer patient Lauri Kershman, M.D., shares her powerful experience as a participant in the John Hopkins Psilocybin Study, supported by the Heffter Research Institute. She discusses how psilocybin impacted her emotional and psychological journey while battling cancer.

A Patient Speaks: Estalyn's Experience with Psychotherapy

Estalyn Walcoff was experiencing existential distress following a cancer diagnosis. She describes the transformative psychedelic experience she had during the NYU Psilocybin Cancer Anxiety Study and how it shifted her perspective on the situation.

ARTICLES

Seeking Relief From Brain Injury, Some Veterans Turn to Psychedelics

In December 2024 the New York Times published an article featuring The Mission Within. They are an organization that utilizes psychedelic therapy to provide treatment for PTSD for Veterans and their spouses. Many of which present complex cases of PTSD, depression & anxiety. A common experience for the participants is that they have previously tried psychotherapy, prescription medications, and nearly everything else the military and veterans’ healthcare systems had to offer without success.

FDA Calls Psychedelic Psilocybin a 'Breakthrough Therapy' for Severe Depression

This article, published in 2019 in Livescience, describes how the U.S. Food and Drug Administration (FDA) has designated psilocybin therapy—currently being tested in clinical trials—as “breakthrough therapy,” an action meant to accelerate the typically sluggish process of drug development and review.

American Journal of Psychiatry - Full Issue

In January 2025, the American Journal of Psychiatry (AJP) published a special issue titled “The American Journal of Psychiatry—Special Issue on Psychedelics (Volume 182, Number 1).” It contains multiple articles that detail the latest studies and up-to-date information on psychedelics. It addresses many of the ongoing challenges and looming questions in the field of psychiatric psychedelic research and treatment.

Psychedelics and Psychedelic-Assisted Psychotherapy

An article published in January 2025 in the American Journal of Psychiatry (Vol. 182) reviews 14 clinical trials (2007-2019) that examined the clinical evidence, safety, and therapeutic potential of psychedelics (LSD, psilocybin, ayahuasca) and MDMA in psychiatric disorders. Promising results were noted for PTSD (MDMA) and depression (psilocybin). The article concludes that the database is insufficient for FDA, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders is warranted.

Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research

An article published in 2025 in the American Journal of Psychiatry (Vol. 182) expands on the promising results in early-stage clinical trials using psilocybin, combined with therapy to treat depression, anxiety, and other disorders.

Treatment With Psychedelics is Psychotherapy Beyond Reductionism

This article published in 2024 in Lancet Psychiatry proposes that the treatment of psychiatric disorders with psychedelic substances represents one of the most promising current treatment approaches in psychiatry. It argues that the characterization of therapy with psychedelics as a biological intervention (with psychological support as a purely safety-related component) represents an outdated and reductionistic dualism that has dominated psychiatric treatment and research for far too long.

71 TO 100%

of participants attributed positive life changes to their psilocybin-assisted therapy and rated it among the most personally meaningful and spiritually significant experiences of their lives.

Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration

This article was published in 2025 in the American Journal of Psychiatry (Vol. 182) focuses on Veterans Affairs (VA)’s proactive approach to preparing for the potential approval of psychedelic-assisted therapies (PATs) for clinical use. The VA aims to ensure that veterans have access to safe and effective psychedelic-assisted therapies when they become available.

Therapeutic Effects of Classic Serotonergic Psychedelics: A Systematic Review of Modern-Era Clinical Studies

This article, published in 2021 in Acta Psychiatrica Scandinavica, is a review of modern-era clinical studies assessing the therapeutic effects of psychedelic drugs for mental health conditions. Across these studies, a total of 188 patients suffering either cancer- or illness-related anxiety and depression disorders (C/I-RADD), major depressive disorder (MDD), obsessive-compulsive disorder (OCD) or substance use disorder (SUD) were included. It concludes that these studies provide early evidence for treatment efficacy and safety for various psychiatric conditions.

‘This is Medicine’: Inside the Psilocybin Retreat for US First Responders

This article was published in The Guardian on December 29th, 2024, and details the experience of police officers, firefighters, and paramedics flying to Mexico for treatment. Almost every first responder the Guardian spoke with for this story noted that while there are far more resources available now than in years past, such as peer support groups, they argued that the mental health crisis in emergency services has worsened and that this is one of the few options that provides proper relief.

The Moderating Effect Of Psychedelics On The Prospective Relationship Between Prescription Opioid Use And Suicide Risk Among Marginalized Women

This article examines the therapeutic potential of psilocybin for treating depression, anxiety, and other mental health conditions. It highlights the findings of clinical trials that show how psilocybin can induce profound, lasting changes in mood and behavior when combined with psychotherapy. These effects are attributed to the psychedelic’s ability to promote neuroplasticity, enhance emotional processing, and reduce rigid thinking. The review also discusses the safety profile of psilocybin and its role in personalized mental health treatments.

Marine Corps Veteran Juliana Mercer

Shared how psilocybin helped her with PTSD from her time serving in the Middle East.

FDNY Firefighter Joe McKay

Lost 26 colleagues in the 9/11 attacks and wrote about how psilocybin helped him overcome depression and suicidality after years of suffering.

Retired NYPD Detective Ethan Abend

Endured trauma from a home explosion, stated that psilocybin “saved his life.”

What 2025 Could Bring for Psychedelic Use in Healthcare

This article appeared on Pharma on January 13th this year. It summarizes that 2024 was a year of setbacks exemplified by the FDA’s rejection of MDMA as a depression treatment. However, many promising trials are on the horizon in 2025.

The Therapeutic Alliance in Psychedelic-Assisted Psychotherapy: A Novel Target for Research and Interventions

This article, published in 2023 in Psychedelic Medicine, establishes that investigations of the psychotherapy components of psychedelic-assisted therapy (PAT) have lagged behind other work. Years of research on different forms of psychotherapy reveal that one of the most important contributors to outcomes is the therapeutic alliance, a cooperative connection between clients and providers.
Skip to content